Eliciting Patient Preferences
Authors: Hillary A. Llewellyn-Thomas
Journal: Annals of Internal Medicine (1993)

Letters1 January 1993Eliciting Patient PreferencesHillary A. Llewellyn-Thomas, PhD, C. David Naylor, MD, DPhil, and Annette M. O'Connor, PhDHillary A. Llewellyn-Thomas, PhDUniversity of Toronto; Sunnybrook Health Sciences Centre; Toronto, Ontario, CanadaUniversity of Ottawa; Ottawa, Ontario, CanadaSearch for more papers by this author, C. David Naylor, MD, DPhilUniversity of Toronto; Sunnybrook Health Sciences Centre; Toronto, Ontario, CanadaUniversity of Ottawa; Ottawa, Ontario, CanadaSearch for more papers by this author, and Annette M. O'Connor, PhDUniversity of Toronto; Sunnybrook Health Sciences Centre; Toronto, Ontario, CanadaUniversity of Ottawa; Ottawa, Ontario, CanadaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-1-199301010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:An interesting contribution by Levine and colleagues [1] describes a bedside decision board to teach patients with node-negative breast cancer about adjuvant chemotherapy and to elicit their treatment preferences. However, for validation, the stability of preferences should be measured by subtly changing risks and benefits as well as the wording of the decision board [2]. The preferred validation of such an approach is a randomized trial where several specific outcomes are measured including measures of anxiety, regret, and other indices of decisional conflict or uncertainty; intergroup differences in actual treatment choices; compliance with chosen treatments; and direct ...References1. Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992; 117:53-8. Google Scholar2. O'Connor AMC, Boyd NF, Warde P, Stolbach L, Till JE. Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique, and treatment experience on preferences. J Chron Dis. 1987; 40:811-8. Google Scholar3. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med. 1991; 32:35-42. Google Scholar4. Llewellyn-Thomas HA, Thiel EC, Clark RM. Patients versus surrogates: whose opinion counts on ethics review panels? Clin Res. 1989; 37:501-5. Google Scholar Author, Article, and Disclosure InformationAuthors: Hillary A. Llewellyn-Thomas, PhD; C. David Naylor, MD, DPhil; Annette M. O'Connor, PhDAffiliations: University of Toronto; Sunnybrook Health Sciences Centre; Toronto, Ontario, CanadaUniversity of Ottawa; Ottawa, Ontario, Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPatients' preferences and trade-offs for the treatment of early stage hepatocellular carcinomaLive liver donors’ risk thresholds: risking a life to save a lifeCognitive-emotional decision making (CEDM): A framework of patient medical decision makingPsychosocial Determinants and Outcomes of Chemotherapy in Older Women with Breast Cancer 1 January 1993Volume 118, Issue 1Page: 76-77KeywordsAdjuvant chemotherapyAnxietyBreast cancerCancer treatmentClinical trialsEmotionsHealth care qualityRandomized trials ePublished: 15 August 2000 Issue Published: 1 January 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...